Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective Study
Antonella Di Cesare(University of Florence), Francesca Prignano(University of Florence), Nicola Pimpinelli(University of Florence), Salvatore Panduri(University of Pisa), Michela Magnano(Ospedale Santa Chiara), E Lorenzoni(IMT School for Advanced Studies Lucca), Emanuele Trovato(University of Siena), Martina Dragotto(University of Florence), Eugenio Capalbo(University of Siena), Federica Ricceri(Ospedale San Donato), Leonardo Pescitelli(University of Florence), Elia Rosi(Hidradenitis Suppurativa Foundation), Alessandra Michelucci(University of Pisa), Flavia Manzo Margiotta(Scuola Superiore Sant'Anna), Pietro Rubegni(University of Siena), Marco Romanelli(University of Pisa), Gionata Buggiani(Ospedale San Giuseppe), Susanna Rossari(University of Florence), Nicola Milanesi(Ospedale del Ceppo), Imma Savarese(University of Florence)
Cited by 1
Related Papers
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657
Defining early mycosis fungoides
|Journal of the American Academy of Dermatology|2005|543